Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistMB Solutions, LLC/BioSpectrum CBD was cited for marketing multiple unapproved new drugs containing cannabidiol (CBD), including nasal sprays, topical roll-ons, tinctures, and edible gummies, in violation of sections 505(a) and 301(d) of the Food, Drug, and Cosmetic Act. The company's websites and social media made therapeutic claims for products like "Regular Strength Nasadol CBD Nasal Spray" and "Pain Relief Roll-On" without FDA approval, and failed to include required labeling information in violation of section 502(f)(1). Additionally, the company marketed unapproved new animal drugs, specifically "1,000mg Canine CBD Oil" and "CBD Dog Treats," which were deemed unsafe and adulterated under section 512(a) and 501(a)(5) of the FD&C Act.